#USA #Honolulu #Parkinson's Disease #ND0612 #Mitsubishi Pharma

Mitsubishi Tanabe Pharma America to Unveil New Findings on ND0612

Mitsubishi Tanabe Pharma America, Inc. (MTPA) has excitingly announced it will present groundbreaking data at the upcoming 2025 International Congress of Parkinson's Disease and Movement Disorders®. This prestigious event is set to take place from October 5-9 in Honolulu, HI, where MTPA is scheduled to showcase four poster presentations centered around the investigational product, ND0612.

ND0612 is a pioneering approach to treating Parkinson's disease (PD) that involves a continuous subcutaneous infusion of liquid levodopa/carbidopa. This innovative treatment aims to address the complexities of PD, particularly concerning patients who encounter motor fluctuations — a significant challenge in managing the disease.

Dr. Gustavo A. Suarez Zambrano, Vice President of Medical Affairs at MTPA, expressed enthusiasm about sharing new findings and discussing them with leading experts at this gathering. MTPA's commitment to advancing understanding and innovation within Parkinson's research underscores their dedication to improving patient outcomes.

During the congress, MTPA will present e-posters in Exhibit Hall 1 on October 7, from 12:00 p.m. to 2:30 p.m. HST. The presentations will focus on results from the pivotal Phase 3 BouNDless study (NCT04006210), which was designed to assess the effectiveness of ND0612 compared to standard care for motor fluctuations in PD patients.

Presentation Highlights

1. Pharmacokinetic Analysis of ND0612: This segment will be presented by Jordan Dawson, MSL at MTPA, focusing on how subcutaneous delivery of levodopa/carbidopa is achieved through ND0612. (E-Poster #846; 12:12 p.m. HST)

2. Efficacy of ND0612 Across Disease Stages: Presented by Dr. Harini Sarva from New York Presbyterian Hospital, this analysis will delve into the efficacy of ND0612 concerning patients at various stages of Parkinson’s. (E-Poster #900; 12:24 p.m. HST)

3. Dyskinesia Outcomes: Dr. Alberto Espay from the University of Cincinnati will address how ND0612 impacts dyskinesia, which is a common complication among PD patients. (E-Poster #861; 12:57 p.m. HST)

4. Falling Incidence with ND0612: Dr. Stuart H. Isaacson from the Parkinson's Disease Movement Disorders Center will share supportive analyses from the BouNDless study that highlight how ND0612 contributes to reduced falls. (E-Poster #867; 2:42 p.m. HST)

About ND0612

This investigational treatment is a combination of a drug-device therapy designed for 24/7 delivery of liquid levodopa/carbidopa to manage motor fluctuations in those living with Parkinson’s disease. NeuroDerm, Ltd., an integral part of MTPA, is leading the development and is dedicated to enhancing the quality of life for patients through such innovative solutions.

Company Background

Mitsubishi Tanabe Pharma America is located in Jersey City, N.J., and serves as the dedicated arm for Mitsubishi Tanabe Pharma Corporation in North America, contributing significantly to drug development and commercialization efforts in the pharmaceutical landscape. The overarching mission of MTPC is centered around creating hope for individuals facing various illnesses, including major focuses on CNS, immuno-inflammation, and more.

As the company prepares for this impactful presentation, it paves the way for a promising future in Parkinson's disease management and highlights the importance of collaborative efforts in clinical research. For those attending the congress, MTPA's findings will undoubtedly shed new light on the treatment landscape for Parkinson's disease.

For more insights and updates, visit MTPA's website or follow them on social media.